Next-generation Sequencing Services Market worth $9.37 billion by 2031 - Exclusive Report by MarketsandMarkets™

MarketsandMarkets projects the global next-generation sequencing services market will grow from USD 3.96 billion in 2026 to USD 9.37 billion by 2031, a CAGR of 18.8%. Sequencing services led the market in 2025 with 75.6% share, while North America held 40.9%. The report cites rising demand for outsourced sequencing and advanced data services, and notes MedGenome raised USD 47.5 million in Series E funding in July 2025.

Analysis

The useful signal is a possible shift in outsourced genomics spend toward clinical workflows and data interpretation—not the headline market-growth estimate. If that shift materializes, Labcorp (LH), Eurofins (ERF), and Azenta (AZTA, including GENEWIZ) may capture service revenue, while Illumina (ILMN), Thermo Fisher (TMO), Agilent (A), and sequencing-platform providers benefit only if higher service volumes translate into instrument utilization and consumables demand. These are different earnings exposures: service providers must absorb lab, labor, quality-control, and bioinformatics costs; platform vendors face the risk that outsourcing boosts third-party service capacity without comparable pricing power for equipment.

The report is promotional market research, not company guidance. Its forecast does not establish addressable revenue, market-share gains, margins, or conversion into public-company earnings. Competition and price compression could leave volume growth with limited profit contribution. Long-read adoption may create differentiated work, but it could also require capacity investment before utilization is proven. Clinical testing adoption and reimbursement are the key swing factors over 1–3 years; near-term, the estimate alone is unlikely to justify a durable rerating. The contrarian point: investors may over-credit platform suppliers and underweight the operational economics of service labs. Verify segment-level genomics revenue, realized pricing, utilization, and contract economics before sizing exposure.

Key Decisions for Investors

• No position from the forecast alone. Treat it as a demand signal; wait for LH, ERF, or AZTA disclosures showing NGS revenue growth alongside stable or improving margins before adding service-provider exposure.
• Put AZTA/GeneWiz and LH on a catalyst watchlist: test whether announced collaborations convert into recurring volumes and disclosed economics. One program or partnership is not evidence of material consolidated earnings contribution.
• Monitor ILMN, TMO, A, PACB, and ONT for evidence that outsourced-service growth lifts consumables, platform placements, or utilization—not merely third-party lab throughput. Reassess if guidance or reported segment metrics show volume without improved economics.
• Falsifiers over the next 1–3 quarters: weak sequencing utilization, falling realized prices, margin deterioration at service providers, or clinical adoption/reimbursement setbacks. These would argue that the forecasted market expansion is not translating into investable earnings growth.